Experimental immune cell therapy targets Hard-to-Treat cancers
NCT ID NCT05397093
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial tested a personalized cell therapy called ITIL-306 in people with advanced ovarian, lung, or kidney cancers that had not responded to standard treatments. The therapy uses a patient's own immune cells (TILs) taken from their tumor, modified to better attack cancer cells, and then infused back after a short course of chemotherapy. The study was terminated early after enrolling only one participant, so its safety and effectiveness remain unknown.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ITIL-306 (a cell therapy made from the patient's own tumor-infiltrating lymphocytes, engineered to target FOLR1 on tumors)
What this could lead to
If it works, this could point toward a new treatment option for advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This was a very early phase 1 trial with only 1 participant, and it was terminated early. The approach is complex and involves chemotherapy before the cell infusion, which carries risks like infection and organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States